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Abstract
Germline mutations in BRCA1 predispose carriers to a high incidence of breast and ovarian
cancers. BRCA1 functions to maintain genomic stability through critical roles in DNA repair, cell
cycle arrest and transcriptional control. A major question has been why BRCA1 loss or mutation
leads to tumors mainly in estrogen-regulated tissues, given that BRCA1 has essential functions in
all cell types. Here we report that estrogen and estrogen metabolites can cause DNA double strand
breaks (DSB) in estrogen receptor-α negative breast cells and that BRCA1 is required to repair
these DSBs to prevent metabolite-induced genomic instability. We found that BRCA1 also
regulates estrogen metabolism and metabolite-mediated DNA damage by repressing the
transcription of estrogen-metabolising enzymes, such as CYP1A1, in breast cells. Lastly, we used
a knock-in human cell model with a heterozygous BRCA1 pathogenic mutation to show how
BRCA1 haploinsufficiency affects these processes. Our findings provide pivotal new insights into
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why BRCA1 mutation drives the formation of tumours in estrogen-regulated tissues, despite the
general role of BRCA1 in DNA repair in all cell types.
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INTRODUCTION
BRCA1 is a tumour suppressor protein which functions to preserve genomic stability by
regulating key cellular processes including homologous recombination (HR) mediated DNA
repair, cell cycle checkpoint control, transcriptional regulation, chromatin remodelling and
post-replicative repair (1-3). Despite playing a role in processes essential to all cells, BRCA1
mutation predisposes to tumours predominantly in estrogen regulated tissues, such as the
breasts and ovaries. Indeed, germ-line mutations in a single BRCA1 allele confer a lifetime
risk of up to 90% of developing breast cancer and 30-40% of ovarian cancer (4, 5).
Several observations suggest estrogen has an important role in the development of BRCA1-
dependent breast cancer. Pre- or post-menopausal oophorectomy in BRCA1 mutation
carriers significantly reduces the risk of breast cancer onset and recurrence (6-8).
Furthermore, pregnancy increases the risk of early-onset breast cancer in BRCA1 mutation
carriers, in contrast to non-carriers for whom pregnancy is protective (9). It has also been
reported that BRCA1 represses the expression of CYP19A1 (aromatase), which converts
androgens to bioactive estrogens (10). Thus BRCA1 loss may increase CYP19 expression
and subsequent estrogen production, further driving tumourigenesis (11).
Estrogen is postulated to promote tumourigenesis directly through stimulation of the
estrogen receptor-α (ERα) and the downstream activation of pro-mitogenic transcriptional
programs. However, this is confounded by observations that approximately 70-80% of
BRCA1 mutated breast tumours are ERα negative (12, 13). Furthermore, BRCA1 drives
ERα expression, suggesting the role of estrogen in BRCA1 dependent tumour development
may be independent of ERα (14). Consistent with this, estradiol (E2; the predominant
estrogen) induces tumour formation in ERα knockout mice (15). In these mice, reduction of
endogenous E2, by either oophorectomy or treatment with aromatase inhibitors, delayed
tumourigenesis, whereas the ERα antagonist fulvestrant had no effect (15).
The endogenous conversion of estrogen to genotoxic metabolites has been reported as an
alternative, potentially ERα independent, mechanism for estrogen-dependent breast
tumourigenesis. Estrogen is hydroxylated to form the catechol estrogens 2-hydroxyestradiol
(2-OHE1(E2)) and 4-hydroxyestradiol (4-OHE1(E2)), a process which is catalysed by a
number of cytochrome (CYP) P450 enzymes, including CYP1A1, CYP1A2, CYP1B1 and
CYP3A4. The catechol estrogens are further oxidised (by the same enzymes) into semi-
quinone and quinone forms, the latter of which can react with DNA to form adducts.
Interestingly, urinary levels of 2-OHE2 and 4-OHE2 are elevated in breast cancer patients
compared to healthy controls (16) and 4-OHE2 concentrations have been reported to be up
to 3-times higher in breast cancer biopsies compared to normal breast tissue (17). Moreover,
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in-vivo studies have demonstrated that exogenous 2-OHE2 and 4-OHE2 can induce kidney
and uterine cancers in mice (18, 19). The DNA adducts induced by these metabolites
produce apurinic sites in the DNA which require repair, error-prone repair of which can lead
to A-T to G-C mutations in DNA in the form of G.T heteroduplexes (20-22). Furthermore,
high levels of depurinated estrogen adducts have been observed in serum and urine samples
from breast cancer patients and women with a strong family history of breast cancer (23,
24). It has been suggested that these depurinating adducts are repaired through the
nucleotide excision repair (NER) and base excision repair (BER) pathways, however, a
study which examined chromosomal aberrations in DT40 cells after treatment with 4-OHE2,
observed no difference between wild-type cells and cells depleted of XPA, a key protein in
NER (25, 26). In contrast, there were enhanced chromosomal breaks following 4-OHE2
treatment of rad54 and ku70 mutant DT40 cells, both of which are required for repair of
DSBs by HR and NHEJ, respectively. This suggests that estrogen metabolites may produce
DNA DSBs.
The idea that estrogen metabolites may cause DNA DSBs, coupled with the role of BRCA1
in DSB repair, lead us to hypothesise that BRCA1-deficient cells, may be more susceptible
to estrogen metabolite induced DNA damage and subsequent genomic instability. We
therefore examined whether estrogen and its metabolites 2-OHE2 and 4-OHE2 can cause
DSBs in human breast cells and examined the role of BRCA1 in both the induction and
repair of estrogen metabolite induced DNA damage.
MATERIALS AND METHODS
Cell lines
MCF7 and MCF10A cells were obtained from ATCC and maintained according to the
recommended instrucitons. MCF10A BRCA1 +/− 185delAG and matched control BRCA1
+/+ cells were generated as previously described (27). All cell-lines were verified by STR
profiling.
siRNAs
siRNAs were obtained from Qiagen and reverse transfected into cells using RNAiMAX
(Invitrogen) to a final concentration of 10nM. See Supplementary methods for sequences.
Immunofluorescence Microscopy
Cells were transfected with siRNAs as above and incubated for 48-hours. Cells were then
plated onto coverslips and treated with E2, 2-OHE2 or 4-OHE2 (Sigma), or mock treated
with vehicle and incubated for indicated time points. Cells were then fixed and stained with
γ-H2AX (Millipore), 53BP1 (Millipore), Cyclin A (SCBT) or pATMSer1981 (Cell
Signalling) primary antibodies and imaged using a Nikon Eclipse Ti microscope, using a
60x objective.
Comet assays
Neutral comet assays were carried out using the Cell Biolabs SCGE kit. Comets were scored
using CometScore (TriTek Corp).
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Western Blotting
Western blotting was carried out as previously described (28).
Metaphase spreads, FISH staining and chromosomal aberrations
Analysis was carried out as described previously (29).
qRT-PCR analysis
qRT-PCR was carried out using Roche LightCycler 480 RealTime ready catalogue assays
for each gene (ACTB, CYP1A1, CYP1A2, CYP3A4, CYP1B1, COMT and NQO1) as per the
manufactures instructions. A matched qRT-PCR reaction was carried out using the RT-ve
control for each sample ensuring no genomic DNA contamination.
Chromatin immunoprecipitations (ChIPs)
ChIPs were performed as described previously (28). See supplementary methods for
complete protocol and primer sequences.
Immunohistochemical staining of CYP1A1
Immunohistochemical staining was performed using a fully automated BondMax
immunostainer with a polymer-based peroxidase detection system. (CYP1A1 (B4) SCBT
primary antibody was used at a dilution of 1:50.
Ultra-performance-liquid-chromatography-tandem-mass spectrometry (UPLC-MS/MS)
Samples were extracted using liquid-liquid extraction (LLE) with diethyl ether, followed by
dansyl chloride derivatisation as described by Xu et al. and analysed using UPLC-MS/MS.
See supplementary methods for complete protocol (30).
Isolation and culture or primary breast progenitor cells
See supplementary methods for complete protocol. Ethical approval to obtain primary breast
tissue was granted through the Northern Ireland Biobank. Tissue was dissociated and
mammospheres cultured as previously described (31) in ultra-low attachment 75 cm^2
flasks for 7 days. Mammosphere cultured cells were then dissociated and plated into Lab-
Tek II CC2 treated chamber slides (Nunc) in the media above.
RESULTS
Estrogen metabolites induce DNA DSBs in breast cells
To determine if estrogen metabolites can generate DNA DSBs, we first assessed whether the
parent hormone, Estradiol (E2), induces DSBs in breast cells. Normal like, ERα negative
MCF10A breast cells, were treated with either E2 or mock treated for 3-hours and stained
with the DSB markers 53BP1 and γH2AX. Treatment with E2 resulted in a significant
increase in 53BP1 and γH2AX foci respectively, compared to controls (p<0.001) (Figure
1a-b). To investigate if estrogen metabolites cause DSBs, we treated MCF10A cells with the
metabolic intermediates 2-OHE2 and 4-OHE2 for 3-hours and stained with 53BP1 and
γH2AX. Similar to E2 treatment, we found that both metabolites induced a significant
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increase in DSB foci (p<0.01) (Figure 1c-d). These findings were also confirmed in the ERα
positive breast cancer cell line, MCF7, indicating that E2 metabolite induced DSB induction
is independent of ERα (Supplementary Figures 1a-b). To further confirm that 2-OHE2 and
4-OHE2 induce DSBs, we performed neutral comet assays. Indeed, MCF10A cells treated
with 2-OHE2 and 4-OHE2 demonstrated a greater percentage of tail DNA, tail moment and
tail length, indicative of increased DSBs (Figures 1e-f & Supplementary Figures 1c-d).
DNA DSBs are known to result in activation of the ATM kinase, which is activated through
autophosphorylation of ATM at serine-1981. In keeping with this, 2-OHE2 and 4-OHE2
treatment resulted in a 2.27-fold and 3.37-fold increase in ATMpSer1981 foci (co-localised
with 53BP1 foci) compared to mock controls (Supplementary Figures 1e-f). Taken together,
this data suggests that 2-OHE2 and 4-OHE2 induce DNA DSBs in breast cells.
Interestingly, when carrying out these experiments, we consistently observed uneven
distribution of estrogen metabolite induced DSBs and rather than all cells containing slightly
more foci than mock treated cells, we consistently observed that a fraction of cells (approx.
25-30%) incurred a greater number of DNA DSBs following 2-OHE2 and 4-OHE2
treatment. For example, in cells treated with 2-OHE2, 23% had no 53BP1 foci, whereas 26%
of cells had 6 or more foci (Figure 1g). This suggested that estrogen metabolite mediated
DNA damage may be affected by cell cycle distribution. To test this, we co-stained 2-OHE2
and 4-OHE2 treated MCF10A cells with γH2AX and cyclin-A, which is specifically
expressed during S and G2 phases of the cell cycle. We found that the vast majority of
estrogen metabolite mediated DNA damage occurred in cyclin-A positive cells, suggesting
that 2-OHE2 and 4-OHE2 specifically induce DNA damage during S/G2 phase cells (Figures
1h-i). To confirm this, MCF10A cells treated with 2-OHE2 and 4-OHE2 were pulse labelled
with 5-ethynyl-2′-deoxyuridine (EdU), which is incorporated into DNA during replication.
Cells were then co-stained for γH2AX and EdU. Indeed, significantly more γH2AX foci
were observed in EdU positive cells compared to EdU negative cells following estrogen
metabolite treatment (Supplementary Figure 1g-h). This suggests that the DNA DSBs
produced by 2-OHE2 and 4-OHE2 treatment occur specifically during S-phase.
Estrogen metabolite-mediated DNA damage is exacerbated by BRCA1 loss and not
efficiently repaired in BRCA1-deficient cells
BRCA1 is known to play a pivotal role in DNA DSB repair. Additionally, a role for BRCA1
in the post-replicative repair of bulky DNA adducts induced by UV, which are structurally
similar to E2 metabolite adducted bases, has been recently described (3). In light of this, we
examined if BRCA1 was required for the repair of estrogen induced DSBs. Endogenous
BRCA1 expression was depleted using two independent siRNAs (siBRCA1) compared to a
non-targeting scrambled siRNA (siSCR) and the cells treated with 2-OHE2 and 4-OHE2 for
3-hours. Cells were then allowed to recover for twenty-four hours following treatment,
before being fixed and stained for 53BP1 and γH2AX (Figure 2a-c & Supplementary Figure
2a-b). No significant difference in 53BP1 and γH2AX foci number was observed in siSCR
cells treated with 2-OHE2 or 4-OHE2 relative to untreated control cells, suggesting that
DSBs generated during estrogen metabolite treatment had been efficiently repaired. In
contrast, significantly more 53BP1 and γH2AX foci remained in BRCA1-depleted cells
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treated with 2-OHE2 and 4-OHE2 compared to controls (p<0.001), indicating that BRCA1 is
required for efficient repair of E2-metabolite induced DSBs. This was visualised at multiple
time-points following 3-hours of 2-OHE2 or 4-OHE2 treatment (Supplementary Figure 2c
d). Additionally, given that E2-metabolites induce DNA damage during S-phase, taken
together with the known role for BRCA1 in the post-replicative repair of bulky DNA
adducts, we assessed whether depletion of BRCA1, using two independent siRNAs, caused
replication fork stalling, marked by residual pS4/8 RPA32 foci (3). Consistent with a role
for BRCA1 in repairing E2-metabolite induced DNA damage in s-phase cells, we observed a
dramatic increase in pS4/8 RPA32 positive cells upon BRCA1 depletion following 2OHE2
and 4OHE2 treatment (Figure 2d).
We next examined if 2-OHE2 and 4OHE2 treatment also induced chromosomal instability in
BRCA1-depleted cells. We assessed chromosomal aberrations in control and BRCA1-
depleted MCF10A cells 24-hours following treatment with 2-OHE2 and 4-OHE2. Structural
rearrangements were visualised and quantified in metaphase spreads using chromosome 1 &
2 FISH staining (Figure 2e-f). BRCA1 depletion resulted in a marked increase in
chromosomal aberrations following both 2-OHE2 and 4-OHE2 treatment, demonstrating that
E2 metabolite treatment induces genomic instability in BRCA1-deficient cells. Intriguingly,
when we examined DSB production in these cells immediately following 2-OHE2 and 4-
OHE2 treatment (3-hours) we found that 2-OHE2 and 4-OHE2 treatment resulted in a
significant increase in 53BP1 and γH2AX foci in BRCA1-depleted cells compared to
control cells (Figure 2g-h & Supplementary Figure 2e). Additionally, similar to that
demonstrated earlier, E2 metabolite mediated DNA damage occurred specifically in S/G2
phase of the cell cycle in BRCA1-depleted cells (Supplementary Figure 2f). Due to the
relatively short treatment time (3-hours), it is unlikely that this increase in DSBs observed in
BRCA1-depleted cells is due solely to defective DNA repair. To confirm that this occurred
at early time points and was not confounded by the dose and/or time points of E2-metabolite
treatment used, we assessed γH2AX marked DNA damage in control and BRCA1-depleted
cells following treatment with 1nm, 10nm, 100nm and 1μM E2, 2-OHE2 and 4-OHE2 at
various time-points (Supplementary Figure 3a-c). This revealed increased DNA damage in
BRCA1-depleted cells at all doses and treatment time-points assessed.
Taken together, these data indicate that loss of BRCA1 expression results in delayed repair
kinetics but also increased levels of DNA damage following treatment with E2 metabolites.
To further confirm this, we examined induction and repair of DNA DSBs following 2-OHE2
and 4-OHE2 treatment in BRCA1 mutant MDA-MB-436 cells stably transfected with either
empty vector (EV) or a BRCA1 expression plasmid (Supplementary figure 4a-c). Like,
BRCA1-depleted cells, this revealed increased DNA damage induction at short time points
(3-hours) in the BRCA1-deficient cells (Supplementary figure 4b). Similarly, defective
repair of 2-OHE2 and 4-OHE2 induced DSBs was observed in BRCA1-deficient cells in
comparison to BRCA1 reconstituted cells (Supplementary figure 4c).
Given that BRCA2 is also involved in HR mediated DSB repair and mutations in this gene
also predispose to tumours in the breast and ovaries, we examined the effect of BRCA2
depletion on 2-OHE2 and 4-OHE2 induced DNA damage in both MCF10A and MCF7 cells.
Intriguingly, BRCA2 depletion resulted in slightly increased DSBs following treatment with
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2-OHE2 and 4-OHE2 for 3-hours, which appeared to remain unrepaired at 24-hours
following recovery from 2-OHE2 and 4-OHE2 treatment (Supplementary Figure 5).
Nevertheless, the increased level of DNA damage observed following treatment with 2-
OHE2 and 4-OHE2 in BRCA2 depleted cells was minimal in comparison to that observed in
BRCA1-depleted cells. Additionally, the defective repair of these DSBs in BRCA2 depleted
cells is consistent with BRCA2’s role in HR mediated DSB repair.
BRCA1 regulates the expression of estrogen metabolising enzymes
We have previously proposed that BRCA1 may transcriptionally repress the expression of
estrogen metabolising genes. Specifically, we have demonstrated that CYP1A1, the enzyme
responsible for conversion of E2 to 2-OHE2 and semi-quinone/quinone metabolites, is
repressed by BRCA1 in a number of breast cancer cell lines (32). Additionally, BRCA1 has
been found to transcriptionally activate a number of detoxification/antioxidant genes
including NAD(P)H Quinone Oxoreductase 1 (NQO1), which reduces genotoxic quinones
to non-reactive hydro-quinones (33). This led us to hypothesise that the exacerbated DNA
damage observed in BRCA1-depleted cells at short time points following 2-OHE2 and 4-
OHE2 treatment may be due, at least in part, to increased estrogen metabolism in these cells,
mediated by upregulated expression of estrogen metabolising enzymes, and/or down-
regulated expression of detoxification enzymes such as NQO1. To assess this, we examined
the expression of a panel of estrogen metabolising and detoxification genes including
CYP1A1, CYP1B1, CYP1A2, CYP3A4, NQO1 and COMT, using qRT-PCR, in MCF10A and
MCF7 cells transfected with control and BRCA1 depleting siRNAs (Figure 3a-b). This
revealed that CYP1A1 and CYP3A4 are consistently upregulated upon BRCA1 loss,
suggesting BRCA1 represses the expression of these genes. Additionally, NQO1 was
consistently down-regulated upon BRCA1 depletion in both cell lines. We also examined
the expression of these genes in BRCA1-mutant MDA-MB-436 cells, stably transfected
with EV or BRCA1 (Figure 3c). Ectopic expression of BRCA1 in these cells repressed
expression of CYP1A1, but had a limited effect on CYP3A4 and NQO1 expression.
To assess if BRCA1 regulates the transcription of these genes directly, we performed
BRCA1 Chromatin Immunoprecipitation (ChIP)-qPCR assays from MCF10A cells, using
primers specific to the promoter regions of CYP1A1, CYP3A4, NQO1 and COMT as a
negative control (Figure 3d). We observed enrichment of BRCA1 at all of these promoters
with the exception of COMT, which is neither transcriptionally regulated by BRCA1 nor
promoter bound by BRCA1.
To confirm that this occurs in BRCA1-deficient tumours, we assessed the levels of
CYP1A1, the most highly de-regulated gene upon BRCA1 loss, using
immunohistochemistry (IHC) in a panel of 21 BRCA1 mutant and 75 BRCA1 wild-type
breast tumours. Intratumoural CYP1A1 expression was scored by a pathologist and an
independent scorer as very weak/absent = 1, moderate = 2 or strong = 3 (Figure 3e-f). This
revealed that the mean expression of CYP1A1 expression is significantly upregulated in this
cohort of BRCA1 mutant tumours compared to BRCA1 wild-type sporadic tumours (p =
0.0007).
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Given that we observed a slight increase in E2-metabolite induced DNA damage in BRCA2
depleted cells treated with 2-OHE2 and 4-OHE2 we also assessed the role of BRCA2 in
regulating the expression of CYP1A1 in both MCF10A and MCF7 cells (Supplementary
figure 6a-b). This revealed no significant difference in CYP1A1 expression between control
and BRCA2-depleted cells.
BRCA1 supresses estrogen metabolite mediated DNA damage by suppressing estrogen
metabolism
As BRCA1-depletion results in increased levels of CYP1A1 and CYP3A4 enzymes and
decreased NQO1 expression, we hypothesised that the levels of 2-OHE2 and 4-OHE2 and
2,3/3,4 quinone products would be increased in BRCA1-depleted cells compared to control
cells following E2 treatment. Quinone and semi-quinone metabolites are extremely unstable
and have a very limited half-life making them difficult to quantify. In contrast, 2-OHE2 and
4-OHE2 (which are generated by CYP1A1 and CYP3A4 in breast cells) are relatively stable.
We therefore developed an ultra-performance-liquid-chromatography-tandem-mass
spectrometry (UPLC-MS/MS) method for the detection of 2-OHE2 and 4-OHE2. The
method was optimised for baseline chromatographic separation and the accurate
identification and quantification of both isomeric forms of the hydroxyl-estradiol metabolite
(Figure 4a). Using this method, we found that the relative concentration of 2-OHE2 and 4-
OHE2 was significantly higher in BRCA1-depleted cells compared to control cells (p<0.05)
(Figure 4b).
As CYP1A1 was the most robustly up-regulated estrogen metabolising gene upon BRCA1
depletion, we sought to examine the role of this enzyme in estrogen dependent DNA
damage. To investigate this, BRCA1 and CYP1A1 were co-depleted in MCF10A cells and
DNA DSBs assessed 3-hours following treatment with E2 (Figure 4c-d). BRCA1 and
CYP1A1 depletion was assessed by qRT-PCR (Supplementary Figure 6c-d). Strikingly,
CYP1A1 depletion lead to a marked reduction in estrogen mediated DSBs in BRCA1-
depleted cells (p<0.001), suggesting that estrogen mediated DNA damage in BRCA1-
depleted cells is, at least in part, due to increased CYP1A1 levels in these cells.
This suggests that BRCA1, apart from mediating repair of E2-metabolite mediated DNA
damage, transcriptionally regulates estrogen metabolising enzymes and subsequently
represses estrogen metabolism, thereby protecting cells against estrogen induced DNA
damage. This is particularly important in breast and ovarian cells, which are exposed to
much higher levels of estrogen than other tissues within the body (34). Nevertheless, to
confirm whether this mechanism may drive genomic instability in non-breast cells, we
assessed E2-metabolite induced DNA damage in HEK293, kidney cells (Supplementary
Figure 6e-f). This revealed that, although 2-OHE2 and 4-OHE2 are capable of inducing
DNA DSBs in these cells, they induce much lower levels of DSBs in comparison to breast
cells. Additionally, 2-OHE2 and 4-OHE2 treatment (3-hours) did not induce increased levels
of DSBs in BRCA1-depleted cells (Supplementary Figure 6e). Moreover, we observed
similar, low-levels of DNA damage in both BRCA1 and BRCA2 depleted cells. In contrast,
consistent with the role of BRCA1 and BRCA2 in DSB repair, both BRCA1 and BRCA2
were required for repair of E2-metabolite induced DNA damage in these cells
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(Supplementary Figure 6f). Given that much lower levels of DNA damage were observed in
these cells and that we did not observe any increased DNA damage in BRCA1-depleted
cells in comparison to control, or BRCA2 depleted cells, we hypothesised that BRCA1 may
not regulate the expression of CYP1A1 in these cells. Intriguingly, we were unable to detect
any CYP1A1 transcript in these cells, suggesting that these cells may not metabolise
estrogen at the same rate as breast cells (data not shown).
Estrogen metabolite mediated DNA DSBs are exacerbated in BRCA1 heterozygous breast
cells
Taken together, our data suggests that in BRCA1-deficient breast cells, de-regulated
estrogen metabolism results in increased levels of genotoxic metabolites resulting in
increased DNA damage which, coupled with defective DNA repair, leads to genomic
instability, a key hallmark of cancer initiation and progression. However, clinical evidence
suggests a direct role for estrogen in breast cancer development in BRCA1 mutation
carriers, suggesting that heterozygous loss of BRCA1 may result in haploinsufficiency in at
least one of BRCA1’s functions. Indeed, a number of studies have reported increased
sensitivity to ionising radiation in BRCA1 carrier/heterozygous cells suggesting that DNA
DSB repair may be impaired in carriers (35). Additionally, a recent study by Konishi et al.,
using somatic cell gene targeting to introduce the common pathogenic BRCA1 mutation
185delAG into a single BRCA1 allele in MCF10A cells, demonstrated that this
heterozygous BRCA1 mutation confers impaired HR mediated DSB repair, hypersensitivity
to genotoxic stress and increased genomic instability (27). We therefore set out to determine
if heterozygous mutation of BRCA1 impacts estrogen metabolite mediated DNA damage
and estrogen metabolism.
Using the same cell line model developed by Konishi et al., heterozygous BRCA1
185delAG (BRCA1+/−) and control (BRCA1+/+) MCF10A cells were treated with 2-OHE2
and 4-OHE2 for 3-hours and the media replaced with normal media for 24-hours, before
fixing and staining for 53BP1 and γH2AX. Consistent with a defect in BRCA1 function, a
significant number of unresolved DNA damage foci were visible in 2-OHE2 and 4-OHE2
treated BRCA1+/− cells in comparison to control BRCA1+/+ cells (p<0.001) (Figure 5a).
Surprisingly, the level of unrepaired DNA DSBs was similar to that observed in BRCA1-
depleted MCF10A cells, suggesting that BRCA1 haploinsufficiency imparts a major defect
in repair of E2-metabolite mediated DNA damage. We next examined if, estrogen
metabolites generate more DSBs in BRCA1+/− cells. Indeed, although short term (3-hours)
2-OHE2 and 4-OHE2 treatment induced DNA damage in BRCA1+/+ cells, significantly
more DNA DSB foci were observed in BRCA1+/− cells (p<0.01) (Figure 5b). In support of
this, we treated normal primary breast progenitor cells, isolated from breast tissue obtained
from a woman undergoing elective breast reduction, as well as BRCA1+/− primary breast
progenitor cells from a BRCA1 mutation carrier undergoing a risk-reducing mastectomy,
with both 2-OHE2 and 4-OHE2 and examined both DNA damage induction at 3-hours post
treatment, as well as their ability to repair E2-metabolite induced DNA damage 24-hours
following treatment with 2-OHE2 and 4-OHE2. In keeping with our previous findings, 2-
OHE2 and 4-OHE2 treatment for 3-hours induced more DNA damage in the BRCA1+/−
mammary progenitor cells compared to the BRCA1 wild-type cells and this DNA damage
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was not repaired as efficiently in the BRCA1+/− cells compared to the BRCA1 wild-type
cells (Figure 5c-d). Taken together this data suggests that like BRCA1-depleted cells,
BRCA1+/− cells may have increased rates of estrogen metabolism as well as defective repair
of E2-metabolite induced DNA damage.
To examine this, we assessed the expression levels of the same panel of estrogen
metabolising and detoxification enzymes in BRCA1 +/+ and BRCA1 +/− cells. Indeed, as in
BRCA1-depleted cells, CYP1A1 and CYP3A4 were upregulated in BRCA1+/− compared to
BRCA1+/+cells (Figure 5e). Intriguingly, NQO1 expression was maintained at similar levels
in both cells lines suggesting that BRCA1 haploinsufficiency does not negatively impact all
BRCA1 regulated transcriptional targets. Finally, consistent with the defective DSB repair
observed in these cells following 2-OHE2 and 4-OHE2 treatment, we found that treatment
with either of these metabolites induced genomic instability in BRCA1 +/− cells but not
BRCA1 +/+ cells (Figure 5f).
DISCUSSION
One of the most perplexing features of BRCA1 biology, is that despite playing a central role
in the DNA damage response and DSB repair pathways in all cells, mutation carriers
predominantly develop tumours in the breast and ovaries; both estrogen driven tissues
exposed to high levels of estrogen. Here, we show that treatment with both E2 and the E2-
metabolites 2-OHE2 and 4-OHE2, induces DNA DSBs in human breast cancer cells in an
ERα independent manner. We also found that E2-metabolite mediated DSBs occur
specifically in S-phase cells, suggesting that induction of these lesions is coupled to DNA
replication. We hypothesise that E2-metabolite adducted DNA bases represent replication
barriers, which lead to replication fork stalling during DNA synthesis. Indeed, a number of
studies have shown that 4-hydroxyequilenin (4-OHEN) a metabolite of the equine estrogen
equilenin (which is almost identical to 4OHE-2 in humans) causes identical DNA-adducts to
those caused by 4-OHE2 and that these adducts cause replication fork stalling (36, 37).
In general, stalled replication forks do not collapse and form DSBs, but are instead stabilised
by the ATR kinase through the signalling and recruitment of a plethora of checkpoint
signalling and repair proteins, resulting in resolution of the stalled fork through a HR-
mediated repair process involving BRCA1. However, recent studies have shown that E2
inhibits ATR signalling, suggesting that E2 and its metabolites may lead to replication fork
stalling and subsequent fork collapse and DSB formation through the combined effect of
replication fork stalling and ATR inhibition (38). Further to this, BRCA1 has been shown to
be required for both resolution of stalled replication forks as well as HR mediated repair of
DSBs caused following stalled fork collapse (39). BRCA1 is also required for the removal
and repair of bulky base adducts, a mechanism through which BRCA1 may supress adduct
induced mutagenesis (3). Consistent with this, we observed a dramatic increase in pS4/8
RPA32 positive cells, upon BRCA1 depletion in 2OHE2 and 4OHE2 treated cells.
Interestingly, we found that BRCA1 depletion also resulted in increased levels of E2-
metabolite induced DNA damage, even at very early time points. This suggested that
BRCA1 may also play a more direct role in regulating the physical levels of DNA damage
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induced by estrogen metabolites. Previous data from our laboratory had indicated that
BRCA1 loss leads to upregulation of CYP1A1, a major regulator of E2 metabolism in breast
tissues (32). We therefore tested whether BRCA1 may also regulate the expression of other
estrogen metabolising enzymes, thereby regulating the levels of estrogen derived
metabolites. This analysis revealed that BRCA1 directly represses the transcription of
CYP1A1 and CYP3A4 and promotes the expression of the NAD(P)H:quinone
oxidoreductase, NQO1. We confirmed, using IHC in a cohort of BRCA1 mutant and
matched BRCA1 wild-type tumours, that CYP1A1, the major enzyme involved in
conversion of E2 to 2-OHE2 in breast tissues, is significantly upregulated in BRCA1 mutant
tumours. This is consistent with the increased levels of both 2-OHE2 and 4-OHE2 observed
in BRCA1-depleted cells. We also demonstrated that depletion of CYP1A1 significantly
reduces the amount of DNA damage induced in BRCA1-depleted cells exposed to short
term E2 treatment, confirming that E2-mediated DNA damage in BRCA1-depleted cells is,
at least in part, due to increased estrogen metabolism. Intriguingly, when examining the
impact of BRCA2 on estrogen metabolite-induced DNA damage, we found that although
BRCA2 is required for the repair of these breaks, loss of BRCA2 does not lead to
deregulated estrogen metabolism and the associated increased DNA damage. Perhaps this
explains why BRCA2 mutations are less penetrant than BRCA1 mutations in predisposing
carriers to breast and ovarian cancers.
We have also demonstrated that 2-OHE2 and 4-OHE2 treatment leads to increased DSB
production in MCF10A cells and primary breast cells harbouring a pathogenic heterozygous
BRCA1 mutation, and that like BRCA1-depleted cells, these cells are unable to repair E2-
metabolite mediated DNA damage leading to increased genomic instability. Importantly, we
found that BRCA1 heterozygous mutant cells also have upregulated levels of CYP1A1 and
CYP3A4, suggesting that increased estrogen metabolism may contribute to E2-mediated
DNA damage in these cells. Consistent with this, higher levels of urinary excreted 2-OHE2
and 4-OHE2 have been observed in BRCA1 carriers compared to healthy control women
with no BRCA1 mutation (40).
Taken together, these findings suggest that exposure to estrogen and its subsequent
metabolism in BRCA1-deficient breast cells, is capable of driving genomic instability, a
well-defined early event in breast cancer development. Given that estrogen levels in normal/
benign breast tissue are known to be 6-7 times that of circulating estrogen levels, our
findings suggest a mechanism through which BRCA1 carriers, through enhanced production
of DNA damaging estrogen metabolites, may acquire the genetic alterations that initiate
neoplastic transformation in breast tissue (34). Similarly, levels of estrogen in ovarian
tissues greatly exceed that of circulating estrogen, suggesting that this model may also
explain the substantially increased risk of ovarian cancer in BRCA1 carriers (41).
A phase III trial termed, Prevention of Breast Cancer by Letrozole in Postmenopausal
Women carrying a BRCA1/2 Mutation (LIBER), (ClinicalTrials.gov number,
NCT00673335) is currently enrolling postmenopausal women for treatment with letrozole,
an Aromatase Inhibitor (AI), to evaluate its ability to prevent the development of breast
cancer in patients with a BRCA1/2 mutation. Our results coupled with the finding that
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aromatase levels are substantially higher in prophylactic mastectomy and oophorectomy
tissue from BRCA1 carriers (10), provides further mechanistic data to support this approach.
However, AIs may have little preventative effect in premenopausal women, in whom the
majority of BRCA1-linked tumours develop, and in whom estrogen production occurs
predominantly in the ovaries through an aromatase independent biosynthesis pathway. In
these women, oophorectomy has been shown to reduce the risk of breast cancer by up to
60% (42). Taking our findings into account, it may also be worth considering the use of AIs
as an additional chemopreventative strategy in premenopausal women, whom have
undergone risk-reducing oophorectomy without mastectomy.
Finally, in premenopausal women who have opted not to undergo risk-reducing
oophorectomy or mastectomy, Luteinising hormone releasing hormone agonists (LHRHa’s),
may prove useful as chemopreventative agents. These drugs cause reversible ovarian
suppression/ablation and are currently used in combination with tamoxifen or AIs for the
treatment of premenopausal women with ERα positive breast cancer (43, 44).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Estrogen and its metabolites cause DNA double strand breaks in S/G2 phase cells
A) Representative images of 53BP1 and γ-H2AX marked DNA DSBs in MCF10A cells 3-
hours after mock treatment or treatment with10nM Estradiol (E2). B) Quantification of
53BP1 and γ-H2AX foci in cells described above. Bars represent mean number of foci per
cell +/− SEM from three independent experiments (>200 cells were counted per
experiment). Significance of changes in foci numbers were assessed using students two-
tailed t-test C) Representative images of 53BP1 and γ-H2AX marked DNA DSBs in
MCF10A cells 3-hours after mock treatment or treatment with1μM 2-OHE2 or 4-OHE2. D)
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Quantification of 53BP1 and γ-H2AX foci in cells described above. E) Representative
comet images of MCF10A cells treated as above and subjected to neutral single cell
electrophoresis. Fluorescence intensity mapping of comet images has been applied using
CometScore. F) Quantification of tail DNA in comets from above. Tail DNA was quantified
using CometScore. Bars represent mean percentage of DNA in comet tails, +/− SEM, from
three independent experiments (>100 comets were scored per experiment). G) Frequency
distribution of 53BP1 and γ-H2AX foci in MCF10A cells treated with 2-OHE2 or 4-OHE2
H) Representative images of γ-H2AX marked DNA DSBs in MCF10A cells 3-hours after
mock treatment or treatment with 1μM 2-OHE2 or 4-OHE2. Cells were also stained with
Cyclin-A antibodies to identify cells in S/G2-phase. I) Quantification of γ-H2AX foci in
Cyclin-A positive and negative cells treated as above.
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Figure 2. BRCA1 represses estrogen metabolite mediated DNA DSBs and is required for their
repair
A) Representative western blot demonstrating BRCA1 knockdown in MCF10A cells. B)
Representative images of 53BP1 and γ-H2AX marked DNA DSBs in control (siSCR) and
BRCA1-depleted (siBRCA1) MCF10A cells, 24-hours after treatment with 2-OHE2 or 4-
OHE2 (1μM 3-hours). C) Quantification of 53BP1 and γ-H2AX foci in cells described
above. Bars represent mean number of foci per cell +/− SEM from three independent
experiments (>200 cells were counted per experiment). D) Quantification of cells containing
>3 pS4/8-RPA foci (indicative of stalled replication forks) in control (siSCR) and BRCA1-
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depleted cells (siBRCA1 & siBRCA#2) treated with 2-OHE2 or 4-OHE2 (1μM 3-hours). E)
Representative metaphase spreads of control (siSCR) and BRCA1-depleted (siBRCA1)
MCF10A cells 24-hours after treatment with 2-OHE2 or 4-OHE2 (1μM 3-hours). Spreads
were stained with FISH probes against chromosome 1 (Green) and Chromosome 2 (Red) in
order to visualise gross chromosomal aberrations. F) Quantification of chromosomal
aberrations in metaphase spreads from cells described above (>100 metaphases were scored
per experiment). G) Representative images of 53BP1 and γ-H2AX marked DNA DSBs in
MCF10A cells 3-hours after mock treatment or treatment with 1μM 2-OHE2 or 4-OHE2. H)
Quantification of 53BP1 and γ-H2AX foci in cells described above.
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Figure 3. BRCA1 transcriptionally regulates estrogen metabolizing genes
A-B) qRT-PCR determined expression of genes involved in estrogen metabolism in control
(siSCR) and BRCA1-depleted (siBRCA1) MCF10A (a) and MCF7 (b) cells. Gene
expression was normalised to ACTB expression and is shown relative to expression in
control (siSCR) cells. Bars represent mean relative expression +/− SEM from three
independent experiments. C) qRT-PCR determined expression of genes as above in the
BRCA1-deficient MDA-MB-436 cells stably transfected with either empty vector (+EV) or
a BRCA1 expression plasmid (+BRCA1). D) BRCA1 Chromatin Immunoprecipitation
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(ChIP) qPCR using primers targeting the promoters of COMT (not regulated by BRCA1),
CYP1A1, CYP3A4 and NQO1. Quantified amounts of immunoprecipitated DNA were
normalised to inputs and reported relative to the amount quantified at a non-specific control
region. Bars represent mean fold enrichment +/− SEM from three independent experiments.
E) Immunohistochemistry (IHC) determined expression of CYP1A1 in BRCA1 mutant, and
matched BRCA1 wild-type breast tumours. CYP1A1 expression in each tumour was scored
as 0= absent, 1 = low, 2 = moderate, or 3 = high. Significance of changes in gene expression
were assessed using students two-tailed t-test - ***p = 0.0007. F). Representative images of
moderate and high CYP1A1 staining in BRCA1 wild-type and BRCA1 mutant breast
tumours.
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Figure 4. BRCA1 Suppresses Estrogen Metabolite Mediated DNA Damage by Suppressing
Estrogen Metabolism
A) UPLC-MS/MS MRM transition (m/z 755.1>521.1) chromatogram from control (siSCR)
MCF10A cell culture medium. The transition (representing loss of one dansyl group at the
O-S bond) detects both isobaric species 2- & 4-OHE2-bisdansyl with baseline
chromatographic separation. Isomer identification was confirmed by ratio of a secondary ion
transition (m/z 755.1>170.2) in comparison with analytical standards. Quantification
accuracy was enhanced by use of isotopically labelled internal standards. B) Levels of 2- &
4-OHE2 in culture medium from control (siSCR) and BRCA1-depleted (siBRCA1)
MCF10A cells quantified by an isotope dilution UPLC-MS/MS method. Cells were cultured
in medium containing 10 nM E2 for 24h prior to media sampling. All values were
normalised to cell counts. Bars represent mean concentration +/− SEM from three
independent experiments (8 replicate cultures). Significance of changes in gene expression
were assessed using Student’s two-tailed t-test with significant changes in concentration data
indicated by; * = p < 0.05. C) Representative images of 53BP1 and γ-H2AX marked DNA
DSBs in BRCA1 and CYP1A1 co-depleted MCF10A cells, 3-hours after mock treatment or
treatment with 10nM Estradiol. Depletion of BRCA1 and CYP1A1 was confirmed by qRT-
PCR (Supplementary figure 6c-d) (E2). D) Quantification of 53BP1 and γ-H2AX foci in
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cells described above (>200 cells were counted per experiment). Significance of changes
indicated by; *** = p < 0.001.
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Figure 5. BRCA1 heterozygosity leads to increased estrogen metabolite mediated DNA damage,
defective DNA repair, and genomic instability and loss of repression of estrogen metabolizing
enzymes
A-B) Quantification of γ-H2AX marked DNA DSBs in BRCA1 wild-type (BRCA1 +/+)
and BRCA1 heterozygous 185delAG (BRCA1 −/+) MCF10A cells, 24-hours after treatment
with 2-OHE2 or 4-OHE2 (a) or immediately following 3-hours of treatment with 2-OHE2 or
4-OHE2 (b). Bars represent mean number of foci per cell +/− SEM from three independent
experiments (>200 cells were counted per experiment). C-D) Quantification of γ-H2AX
marked DNA DSBs as above in BRCA1 wild-type (BRCA1 +/+) and BRCA1 heterozygous
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primary breast progenitor cells 24 hours after treatment with 2-OHE2 or 4-OHE2 (c) or
immediately following 3-hours of treatment with 2-OHE2 or 4-OHE2 (d). E) qRT-PCR
determined expression of genes involved in estrogen metabolism in BRCA1 wild-type
(BRCA1 +/+) and BRCA1 heterozygous 185delAG (BRCA1 −/+) MCF10A cells. Bars
represent mean relative expression +/− SEM from three independent experiments. F)
Quantification of chromosomal aberrations in metaphase spreads from BRCA1 wild-type
(BRCA1 +/+) and BRCA1 heterozygous 185delAG (BRCA1 −/+) MCF10A cells, 24-hours
after treatment with 2-OHE2 or 4-OHE2. Bars represent mean aberrations per metaphase +/−
SEM, from three independent experiments (>100 metaphases were scored per experiment).
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